829P - Early-onset hypothyroidism and survival in patients with advanced renal cell carcinoma treated with first-line sunitinib: Updated overall survival...

Date 27 September 2014
Event ESMO 2014
Session Poster Display session
Topics Cytotoxic agents
Renal Cell Cancer
Complications/Toxicities of treatment
Biological therapy
Presenter Alvaro Pinto
Citation Annals of Oncology (2014) 25 (suppl_4): iv280-iv304. 10.1093/annonc/mdu337
Authors A. Pinto1, M. Garrido2, P. Cruz1, D. Lopez3, F. Zambrana4, C. Aguayo5, J. Feliu1, E. Espinosa1
  • 1Medical Oncology, Hospital Universitario La Paz, 28046 - Madrid/ES
  • 2Medical Oncology, Hospital Universitario Severo Ochoa, Leganés/ES
  • 3Urology, Hospital Universitario La Paz, 28046 - Madrid/ES
  • 4Medical Oncology, Hospital Universitario Infanta Sofía, San Sebastián de los Reyes/ES
  • 5Medical Oncology, Hospital del Henares, Coslada/ES



Renal cell carcinoma is a heterogeneous disease; about 20% of the patients will show progression of the disease as their best response, while 25% will be long-term responders. Nowadays, the identification of potential predictive factors for these drugs is an unmet medical need.


Data from patients with advanced renal cell carcinoma treated with first-line sunitinib were collected from four university hospitals in Spain, from 2006 to 2013. Patients with baseline thyroid dysfunction were excluded. We obtained information regarding clinical and pathological issues, as well as toxicities and clinical course of the disease. Hypothyroidism was defined as a level of TSH > 10 mUI/l in the first 12 weeks of therapy.


A total of 82 patients were analyzed, with a median age of 59,5 years (range 30 – 78). Clinical and pathological characteristics of the patients are summarized in Table 1. In the univariate analysis, there was a better progression-free survival (PFS) in the group of patients with hypothyroidism (19 vs 8 months, p = 0.005); this was also true for OS (41 vs 15 months, p = 0.009). Hypothyroidism was confirmed as an independent prognostic factor in the multivariate analysis, together with MSKCC prognostic group and nephrectomy. ECOG performance status and histology (clear cell / non-clear cell) were not significant for survival in the multivariate analysis.


In our group of patients, the occurrence of hypothyroidism was strongly associated with a better outcome, with improvement both in PFS and OS. This association was confirmed in the multivariate analysis. These data support that the occurrence of hypothyroidism could be an early predictive factor of outcome for patients treated with first-line sunitinib.


All authors have declared no conflicts of interest.